Moderna makes vaccines from genetic instructions, called mRNA
COVID shots
93 cents of each sales dollar in 2025
A cancer vaccine
made with Merck for one patient at a time
Not yet approved
a US launch is planned for 2027
Moderna became famous for one of the two mRNA COVID vaccines. Sales have since collapsed, and the company's future now rests on a cancer vaccine built from each patient's own tumour.
The company · 2 · What exactly does it sell?
Seasonal shots today, a personalised cancer vaccine tomorrow
The vaccines are sold each autumn to governments, pharmacies and health systems. The cancer vaccine has no sales yet: it needs approval first.
The company · 3 · How does it make money?
Almost every dollar comes from COVID shots
Each $1 of sales in 2025
93 centsCOVID vaccines, Spikevax and mNEXSPIKE
Under 1 centthe RSV vaccine, mRESVIA
About 7 centsgrants, partners and fees for keeping plants ready
Most shots are bought in the autumn, so sales swing from quarter to quarter. If the cancer vaccine sells, Moderna and Merck split the costs and profit equally.
Is it a good business? · 4 · What gives it an edge?
It has the only personalised cancer vaccine that passed a large trial
42%fewer melanoma patients had cancer return or died, against Keytruda alone
1,137patients in the trial
12 yearsof US protection from copies once a medicine like this is approved
A rival would need its own years-long trial in each cancer. BioNTech's similar vaccine stopped its bowel cancer trial in August 2026.
Is it a good business? · 5 · What is the catch?
The vaccine business keeps shrinking and loses money
17.5%of US adults took last season's COVID shot
$2.93Blost from operations over twelve months to September 2026
Pfizer and BioNTech sell the larger COVID shot, GSK and Pfizer reached older adults with RSV vaccines first, and few people still want a yearly booster.
Is it a good business? · 6 · What does its record show?
Sales fell nine-tenths from the pandemic peak
Sales, $B
18.5
19.3
6.8
3.2
1.9
2.5
Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025last 12 mo
Sales then$19.3B2022, at the pandemic peak
Sales now$1.9B2025
Latest growth29%third quarter of 2026, a year earlier
Moderna cut research from $4.5B in 2024 to $3.1B in 2025 and expects 2026 sales to grow 15% to 25%. It still loses money over a full year.
Is it a good business? · 7 · How much room is there to grow?
Melanoma alone could be a business of a few billion dollars
112,000Americans expected to be found with melanoma in 2026
About 11,000of them with cancer in nearby lymph nodes, like the trial's patients
About $217,000a year of Keytruda at list price, the yardstick for a new cancer medicine
At full use that is about $2.4B a year in the US, before Merck takes half. Lung cancer, if its trial works, would be far bigger.
Is it a good business? · 8 · Who is in charge?
The long-time chief executive owns 7.6% of the company
Stéphane Bancelchief executive since 2011
7.6%of the shares he owns
1,073,172shares insiders sold in a year, nearly all under plans set in advance
He led Moderna through the pandemic boom and the fall, then cut costs. A new operating chief returned in October 2026 to run manufacturing for the cancer vaccine launch.
The story right now · 9 · How does a personalised cancer vaccine work?
Each patient's dose is built from their own tumour
The tumour is removedSurgery takes it out, and it is read for mutations.
Software picks the targetsUp to 34 mutations the immune system can spot.
One dose made per patientThe goal is about six weeks from surgery.
Every patient is a new batchSlow or costly making limits how many are treated.
Given with Keytruda, the dose teaches the immune system to hunt any cancer cells left behind, so fewer cancers come back.
The story right now · 10 · What changed lately?
A trial success sent the shares soaring, then the full data cooled them
19 Aug 2026the melanoma trial succeeded; the shares nearly tripled that day
22 Oct 2026the full data leaked early; the shares fell about a sixth
End of 2026Moderna plans to ask for US approval
Solid quarter
Lung, kidney and bladder cancer trials are fully enrolled. The third quarter brought a rare profit, but the year will still be a large loss.
The story right now · 11 · What is everyone arguing about?
Is this a one-cancer success, or a platform for many?
Many investors think
The cancer vaccine works, so Moderna is now a cancer company worth paying up for
We think
It has worked in one cancer; Merck takes half, and the price already pays for success in many
We would be wrong if the lung cancer trial succeeds and the launch is priced near a year of Keytruda. Survival benefits are not yet shown.
The price and our view · 12 · What is a share worth?
The price sits far above even our sunny future
$38.97what we think a share is worth · the last close is of that
$38.97our value
Attractive below $31.18
Unattractive above $46.76
$16.70gloomy: the launch is slow and vaccines keep shrinking
$38.97our estimate: sales follow the experts' forecasts
$78.13sunny: cancer sales spread faster and further
Value per share in three futures. None is a prediction of the share price.
We estimate what a share is worth from forecasts that already include the cancer vaccine's launch. Even the sunny case is far below today's price.
The price and our view · 13 · What if it all works?
A big cancer win would pay for only a slice of the price
Priced for successthe kind of bet this is
0.2×if it works
12%kept if it fails
Multiples of the company's value when the bet was last struck, 16 Nov 2026.
We also ask what you get if the cancer vaccine succeeds, and what is left if it fails. Success in melanoma adds little at this price; failure leaves a shrinking vaccine business.
The price and our view · 14 · How could we be wrong?
The biggest danger is that one cancer is all it works in
Lung cancer missesBiggest
Most of the price rests on the vaccine spreading.
Survival not shownUnknown
Insurers may not pay without longer lives.
Vaccines keep shrinkingShowing now
Fewer people take a yearly COVID shot.
Making each doseWatch
Slow manufacturing would limit patients treated.
Patent fights cut both ways: Moderna paid $950M to settle one suit and still sues Pfizer and BioNTech.
The price and our view · 15 · How will we know?
The approval filing and the next trials show how far it reaches
The US accepts the approval filing for melanomaGood sign
The lung cancer trial shows fewer cancers coming backGood sign
The kidney cancer trial disappoints, or the filing slipsBad sign
FEB 202712
Results for the last quarter of 2026. Companies report every three months; this one should say whether the filing went in.
Our view also changes on price alone: if the shares fall to within a fifth of our estimate, we move to Neutral.
The price and our view · 16 · So, what do we think?
A real cancer result, priced as if it had already won everywhere
$38.97our value
Attractive below $31.18
Unattractive above $46.76
UnattractiveHigh conviction
The melanoma result is real. But Merck keeps half, the vaccines keep shrinking, and the price is far above even our sunny estimate. Unattractive is about the price, not the science.
↑ ↓ to move · C for contents
What it does
More about the company
Who it is
Moderna's vaccines carry a set of genetic instructions that tell the body's own cells to make a harmless piece of a virus, so the immune system learns to recognise it. It sells shots against COVID, RSV and, since August 2026, flu to governments, pharmacies and health systems.
Its cancer vaccine works the same way, but it is made for one patient at a time from the mutations in that patient's removed tumour, and given with Merck's Keytruda to stop the cancer returning.
How it makes money
Today almost every dollar comes from seasonal vaccines sold each autumn, mostly COVID shots, so sales swing by quarter: $1.31B in the third quarter of 2026, but $2.53B over twelve months against a loss of $2.93B. If the cancer vaccine is approved, Moderna makes it and Merck shares the selling, and the two split the costs and any profit equally.
Growth and profit
What growth costs
There has been no growth to pay for: sales fell nine-tenths in three years. Moderna cut research from $4.5B in 2024 to $3.1B in 2025 and building spending almost to nothing, and plans about $2.7B of research this year. The loss is shrinking because costs fall, not because sales rise.
Its record
The numbers
Is it growing?Steady
Sales grew 13% over the twelve months to Sep 2026, faster than the −40% in the year to Dec 2025.
Is it profitable?Losing
Operating margin is −116%, down from −62% in the year to Dec 2023.
Does growth pay off?Unclear
Running costs take 144¢ of each sales dollar, up from 14¢ in the year to Dec 2021.
Does it earn good returns?Poor
Shareholders' money lost 35% a year, down from 146% in the year to Dec 2021.
How long can it keep going?Limited
It used $1.97B of cash over the last twelve months, so the $5.17B it holds lasts about 2.6 years at that pace.
Is the balance sheet safe?Net cash
It holds $5.17B of cash against $3.55B of debt, $1.62B more cash than it owes.
Are shares being diluted?Stable
The share count barely moved in 4.8 years, and pay in shares costs 18% of sales.
Why it wins
The evidence
In vaccines there is little to keep a buyer: governments and pharmacies switch on price and data each season.
The cancer vaccine is different. It is the only personalised vaccine with a positive late-stage trial, and BioNTech's version stopped its bowel cancer trial. A US biologic gets 12 years of protection from copies, and a rival needs its own large trial in each cancer. That lead is real, but it has not yet earned a dollar.
Who could beat it
The rivals in full
Pfizer and BioNTech sell the larger COVID vaccine, and Comirnaty's sales are shrinking too. Novavax sells a protein-based shot through Sanofi, and GSK and Pfizer reached the RSV market first. In cancer the closest rival is BioNTech's own personalised vaccine, which failed in bowel cancer.
Each rival
Pfizer and BioNTech's ComirnatyPFEBNTX
a government or pharmacy buys the rival COVID shot
Novavax's Nuvaxovid, sold by Sanofi, and Sanofi's flu vaccinesNVAXSNY
a protein COVID shot or an established flu shot instead of an mRNA one
GSK's Arexvy and Pfizer's Abrysvo against RSVGSKPFE
an older adult takes the RSV vaccine that reached the market first
BioNTech's autogene cevumeran, its own individualized mRNA cancer vaccineBNTX
a rival personalised vaccine for the same patients after surgery
the doctor gives the standard immunotherapy without adding the vaccine
How big it could get
The market and who has signed
The market
About 112,000 Americans will be found with melanoma in 2026, and roughly 11,000 of them with cancer that has reached nearby lymph nodes, the kind the trial treated. A year of Keytruda lists at about $217,000, so melanoma alone could be about $2.4B a year in the US at full use, before Merck takes its half. Lung cancer, if its trial works, would be far larger.
Who has signed
Merck has signed to share the cancer vaccine's costs and profits equally worldwide. Canada, the United Kingdom and Australia have long-term vaccine partnerships with plants built on their soil, and Recordati licensed a rare-disease medicine for $50M upfront.
Who runs it
Leaders, pay and the cash
Who runs it
Stéphane Bancel has run Moderna since 2011 and owns 7.6% of the shares; co-founder and chairman Noubar Afeyan owns 1.8%. A new chief operating officer, Juan Andres, returned in October 2026 to run manufacturing for the launch.
Bancel's bonus paid 170% of target in 2025, while his share awards tied to results vested at about half. Insiders bought no shares in the past year and sold 1,073,172, nearly all under plans set in advance.
The last report
The latest report
Moderna's third-quarter sales rose 29% to $1.31B, with a rare quarterly profit
What it did to the thesis Solid quarter
It helped the vaccine business: sales grew again and costs kept falling. It left the case where it was, because the price rests on the cancer vaccine, which the quarter did not test, and the business still loses money over the year.
The report
In the quarter to September 2026 sales rose 29% to $1.31B and Moderna earned $162M, helped by European sales of $314M against $16M a year earlier. Research spending fell 27%.
Management now expects 2026 sales to grow 15% to 25%, up from up to 10% in January, and year-end cash of $8.1B to $8.3B. Nine months still used $2.72B of cash, including the $950M patent settlement.
What's happening now
The background
The shares nearly tripled on 19 August, the day the melanoma trial succeeded, fell about a sixth on 22 October when the full data leaked early, and slipped after the 12 November analyst day.
Moderna plans to ask for US approval by the end of 2026 and to launch with Merck in 2027. The next tests are the fourth-quarter report in February and a kidney cancer trial reading around the turn of the year.
Where we disagree
Both sides in full
The market
The cancer vaccine works, so Moderna is now a cancer company with a technology worth paying up for.
We believe
The melanoma result is real, but Merck takes half the profit and the vaccines keep shrinking, so even our optimistic value sits far below the price.
The argument
The market has priced the technology as proven in many cancers. It has worked in one, the survival benefit is not yet shown, and a rival's version failed in another.
The evidence against us: if the lung cancer trial succeeds and the launch is priced near a year of Keytruda, the vaccine could be far bigger than the analysts expect.
What it's worth
How we value it
Valued on the analysts' revenue path for three years, each later year closing 30% of the gap to 4%, on official operating profit with stock pay a cost and tax paid in full; the thesis's own evidence is the check on that path. A young business by the measure that counts here, profit not yet earned: stock pay, today 18.4% of sales, fades to a mature 6% by the normal year, the owner's call of 10 November.
The three cases
Bear case$16.70
Growth runs at half the analysts' path, 0.4%, 16.6% and 28.0%, the margin settles a fifth lower at 16.1%, and new capital earns only the 8% rate: intismeran's launch slow and the vaccines still shrinking.
Our value$38.97
Revenue grows 0.8%, 33.2% and 55.9% over three years, the analysts' path (C26) that already carries intismeran's launch, then fades toward 4%, closing 30% of the gap each year; the margin moves to 20.2%, the analysts' 2030 figure after stock pay, which is 18.4% of sales today and fades to a mature 6%.
Bull case$78.13
Growth runs a quarter above the analysts' path, 1.0%, 41.5% and 69.9%, as lung cancer and other tumours follow melanoma, the margin reaches 22.2%, and new capital earns 11%.
The bet
Seen as a bet
This bet is on the cancer vaccine and the rare-disease medicines. It works if the vaccine is approved, launched with Merck and then spreads beyond melanoma.
Even a large win in melanoma, with Moderna's half of the profit, would be worth only a fraction of today's company value. If it fails, shareholders keep a shrinking vaccine business worth a small part of the price, so the bet is priced and expensive.
What could go wrong
Every risk
The risks
Survival not yet shown
The trial proved fewer cancers came back; if lives are not lengthened, insurers may refuse to pay on top of Keytruda.
One medicine carries the price
A miss in lung cancer, or a rival's failure repeating in another tumour, would remove most of what the shares pay for.
Shrinking vaccines
Only about one adult in six took last season's COVID shot, and sales keep falling across the industry.
Making a medicine per patient
Each dose is built from one tumour; slow or costly manufacturing could limit how many patients are treated.
Patents cut both ways
Moderna paid $950M to settle one suit, lost a European patent this year and still sues Pfizer and BioNTech.
What we still do not know
What the cancer vaccine will cost, and whether Medicare will pay for it on top of Keytruda.
Whether fewer cancers coming back turns into longer lives in the melanoma trial.
Whether Moderna can make each patient's dose in about six weeks at commercial scale.
What changes our view
Every route to a new view
Every route to a new view
→ Neutral
The share price falls back within 20% of what we think the business is worth.
→ Attractive
The share price falls to 80% of what we think the business is worth.
→ Neutral
The lung cancer trial reports a clear cut in cancers coming back at its first look. The US approves the vaccine for melanoma at a price near a year of Keytruda.
The next test
It supports the case if
The filing is accepted with priority review, 2026 revenue reaches $2.3B or more, and year-end cash is $8.1B or more.
It pressures the case if
The filing slips, 2026 revenue misses the guide, or 2027 spending rises above $4.5B without new revenue.
We would also be wrong if
COVID, RSV and flu vaccine sales grow again in 2027, with more than a fifth of US adults taking a COVID shot.
The verdict
Scores and how we weighed it
The scores
Growth
1 of 4
Business quality
2 of 4
Financial position
3 of 4
Execution record
2 of 4
Per share capture
2 of 4
Potential
3 of 4
Risk profile
2 of 4
Valuation
1 of 4
Evidence quality
3 of 4
How we weighed it
ValueNegative
The price sits far above our value and above the bull case.
BusinessNegative
The vaccines have no moat and the cancer vaccine has not yet sold.
GrowthMixed
Sales grow again this year, but off a base a tenth of the peak, and the price assumes far more.
RisksNegative
Survival is unproven, a rival's version failed in another cancer, and Merck keeps half.
RivalsNegative
Priced at many times its filed rivals on sales.
The groupMixed
It sits in none of our ranked groups; trial news moves it, not the market.
Latest newsPositive
A positive late-stage trial, a strong quarter and a filing planned by year-end.
In plain words
Our estimate of value
We forecast how much cash the business can earn over the next ten years and beyond, then ask what that stream is worth today to an investor who wants an 8% yearly return. We do it three times: a gloomy future, an expected one and a sunny one. We call a share Attractive only when its price is at least 20% below the expected estimate, and Unattractive when it is 20% above.